Indira IVF Hospital confidentially files for India IPO
ByAinvest
Tuesday, Jul 15, 2025 10:49 pm ET1min read
Indira IVF Hospital confidentially files for India IPO
Indian fertility services provider Indira IVF Hospital has taken a significant step towards going public by filing draft papers confidentially with the country's markets regulator. The news was reported by Reuters and confirmed through various sources, including Bloomberg and Marketscreener.Indira IVF Hospital, founded in 2011, operates over 155 fertility centers and works with 315 IVF specialists across India. The company is backed by private equity firm EQT AB and is seeking to raise approximately 35 billion rupees ($408 million) through its initial public offering (IPO). The IPO will consist solely of existing shares, with EQT AB expected to offload around 29 billion rupees worth of shares. Additionally, three members of the founding family—Ajay Murdia, Kshitiz Murdia, and Nitiz Murdia—will each sell shares valued at about 2 billion rupees [3].
The IPO comes after the company initially submitted a draft prospectus in February but withdrew it in March. The withdrawal was reportedly due to concerns from the Securities and Exchange Board of India (SEBI) about the timing of the IPO, which coincided with the release of a Bollywood biopic based on the company's founder [2, 3].
The IPO is expected to be a significant event in India's healthcare sector, providing investors with an opportunity to invest in a leading fertility services provider. The company's extensive network and expertise in IVF treatments make it a compelling investment option. However, potential investors should carefully consider the risks associated with the healthcare sector and the specific challenges faced by fertility services providers.
Indira IVF Hospital's IPO is being advised by Kotak Mahindra Capital Co., IIFL Capital Services Ltd., JPMorgan Chase & Co., and UBS Group AG [3]. The company's filing with the markets regulator marks a renewed push towards an IPO, with the draft prospectus expected to be submitted later this month [4].
References:
[1] Reuters, "India's Indira IVF Hospital files IPO via confidential route," July 16, 2025, https://www.reuters.com/business/healthcare-pharmaceuticals/indias-indira-ivf-hospital-files-ipo-via-confidential-route-2025-07-16/
[2] Reuters, "Indian fertility services provider Indira IVF Hospital files IPO via confidential route," July 16, 2025, https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3TD051:0-india-s-indira-ivf-hospital-files-for-ipo-via-confidential-route/
[3] Bloomberg, "Indira IVF Said to Revive India IPO That May Raise $408 Million," July 15, 2025, https://www.bloomberg.com/news/articles/2025-07-15/indira-ivf-said-to-revive-india-ipo-that-may-raise-408-million
[4] Marketscreener, "Indira IVF Backed by EQT Revives IPO Plans in India," July 15, 2025, https://www.marketscreener.com/quote/stock/EQT-AB-66480635/news/Indira-IVF-Backed-by-EQT-Revives-IPO-Plans-in-India-Bloomberg-News-50509519/

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet